Corporate Presentation Corporate Presentation ERA 2023 Late Breaking Presentation 36-Week Efficacy & Safety of Atacicept 150 mg in the ORIGIN Randomized, Double-blind, Placebo-controlled Phase 2b Study in IgAN and Persistent Proteinuria ASN 2022 Presentations Atacicept Reduces Serum Immune Complex Levels in IgAN Patients A Randomized Phase 2 Study of MAU868 vs Placebo to Treat BK Viremia in Kidney Transplant Recipients – Week 36 Results ERA EDTA 2022 Presentations 2022 ERA EDTA anti GdlgA1 2022 ERA EDTA April SLE Renal ASN 2021 E-Poster Presentation Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients Investor Calendar and Recordings
36-Week Efficacy & Safety of Atacicept 150 mg in the ORIGIN Randomized, Double-blind, Placebo-controlled Phase 2b Study in IgAN and Persistent Proteinuria
A Randomized Phase 2 Study of MAU868 vs Placebo to Treat BK Viremia in Kidney Transplant Recipients – Week 36 Results
